Opin vísindi

Fletta eftir efnisorði "Antibodies, Monoclonal, Humanized/therapeutic use"

Fletta eftir efnisorði "Antibodies, Monoclonal, Humanized/therapeutic use"

Röðun: Raða: Niðurstöður:

  • Icon
    Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for both 
    Pfeffer, Paul E; Ali, Nasloon; Murray, Ruth; Ulrik, Charlotte; Tran, Trung N; Maspero, Jorge; Peters, Matthew; Christoff, George C; Sadatsafavi, Mohsen; Torres-Duque, Carlos A; Altraja, Alan; Lehtimäki, Lauri; Papadopoulos, Nikolaos G; Salvi, Sundeep; Costello, Richard W; Cushen, Breda; Heffler, Enrico; Iwanaga, Takashi; Al-Ahmad, Mona; Larenas-Linnemann, Désirée; Kuna, Piotr; Fonseca, João A; Al-Lehebi, Riyad; Rhee, Chin Kook; Perez-de-Llano, Luis; Perng Steve, Diahn-Warng; Mahboub, Bassam; Wang, Eileen; Goh, Celine; Lyu, Juntao; Newell, Anthony; Alacqua, Marianna; Belevskiy, Andrey S; Bhutani, Mohit; Bjermer, Leif; Björnsdóttir, Unnur Steina; Bourdin, Arnaud; Bulow, Anna von; Busby, John; Canonica, Giorgio Walter; Cosio, Borja G; Dorscheid, Delbert R; Muñoz-Esquerre, Mariana; FitzGerald, J Mark; Gil, Esther Garcia; Gibson, Peter G; Heaney, Liam G; Hew, Mark; Hilberg, Ole; Hoyte, Flavia; Jackson, David J; Koh, Mariko Siyue; Ko, Hsin-Kuo Bruce; Lee, Jae Ha; Lehmann, Sverre; Chaves Loureiro, Cláudia; Lúðvíksdóttir, Dóra; Menzies-Gow, Andrew N; Mitchell, Patrick; Papaioannou, Andriana I; Popov, Todor A; Porsbjerg, Celeste M; Salameh, Laila; Sirena, Concetta; Taillé, Camille; Taube, Christian; Tohda, Yuji; Wechsler, Michael E; Price, David B (2023-07)
    BACKGROUND: Patients with severe asthma may present with characteristics representing overlapping phenotypes, making them eligible for more than one class of biologic. Our aim was to describe the profile of adult patients with severe asthma eligible ...
  • Icon
    Fyrsta meðferð með tocilizumab við COVID-19 hérlendis - sjúkratilfelli 
    Björnsson, Aron Hjalti; Ólafsdóttir, Þorbjörg; Þormar, Katrín María; Kristjánsson, Már; Þórisdóttir, Anna Sesselja; Lúðvíksson, Björn Rúnar; Gudmundsson, Sigurdur; Gottfreðsson, Magnús (2020-05-06)
    Rúmlega fimmtugur karlmaður sem hafði verið á ferðalagi erlendis veiktist við komuna til landsins með flensulíkum einkennum og greindist með COVID-19. Nokkrum dögum síðar versnandi honum af öndunarfæraeinkennum og lagðist inn á Landspítala. Hann reyndist ...
  • Icon
    Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries 
    Michelsen, Brigitte; Georgiadis, Stylianos; Di Giuseppe, Daniela; Loft, Anne G.; Nissen, Michael J.; Iannone, Florenzo; Pombo-Suarez, Manuel; Mann, Herman; Rotar, Ziga; Eklund, Kari K.; Kvien, Tore K.; Santos, Maria J.; Guðbjörnsson, Björn; Codreanu, Catalin; Yilmaz, Sema; Wallman, Johan K.; Brahe, Cecilie H.; Möller, Burkhard; Favalli, Ennio G.; Sánchez-Piedra, Carlos; Nekvindova, Lucie; Tomsic, Matija; Trokovic, Nina; Kristianslund, Eirik K.; Santos, Helena; Löve, Þorvarður Jón; Ionescu, Ruxandra; Pehlivan, Yavuz; Jones, Gareth T.; van der Horst-Bruinsma, Irene; Ørnbjerg, Lykke M.; Østergaard, Mikkel; Hetland, Merete L. (2022-04-29)
    Objective: There is a lack of real-life studies on interleukin-17 (IL-17) inhibition in psoriatic arthritis (PsA). We assessed real-life 6- and 12-month effectiveness (i.e., retention, remission, low disease activity [LDA], and response rates) of the ...